Diprosone

How to order Diprosone

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Diprosone on Prescriptsy

Diprosone is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Diprosone is a topical corticosteroid preparation containing betamethasone dipropionate 0.05%, classified as a potent (Group III) corticosteroid in the British National Formulary.

It is licensed in the United Kingdom for the treatment of a wide range of inflammatory skin conditions including eczema (atopic dermatitis), psoriasis, contact dermatitis, seborrhoeic dermatitis, neurodermatitis, and other corticosteroid-responsive dermatoses.

Diprosone is available as a cream, ointment, and lotion, providing formulation options suitable for different body sites and skin conditions.

It is manufactured by Organon (formerly MSD) and is a prescription-only medicine.

Inflammatory skin conditions are among the most common reasons for GP consultations in the UK.

Eczema alone affects approximately 1 in 5 children and 1 in 12 adults, while psoriasis affects around 1.8% of the population.

These conditions cause significant discomfort, distress, and impact on quality of life.

Topical corticosteroids have been the mainstay of treatment for inflammatory dermatoses since their introduction in the 1950s, and they remain the first-line anti-inflammatory therapy recommended by NICE, the BAD, and the Primary Care Dermatology Society.

This page provides a comprehensive clinical overview of how Diprosone works, when it is appropriate, correct application technique, expected outcomes, side effects, safety warnings, and how to obtain a prescription in the UK.

Important safety information about Diprosone

Before reading further, note the following essential safety points. Diprosone is a prescription-only medicine (POM) in the UK and should be used under medical supervision.

• Diprosone is a potent topical corticosteroid. Use for the shortest duration necessary and apply only to affected skin.
• Continuous use should generally not exceed 2 to 4 weeks on the body without medical review.
• Do not apply to the face, eyelids, groin, or axillae unless a dermatologist specifically directs this.
• Do not use under occlusive dressings unless instructed by a specialist.
• If the skin becomes thinner, develops stretch marks, or shows signs of infection, stop treatment and seek medical advice.

Understanding inflammatory skin conditions

Inflammatory skin conditions share a common feature: dysregulated immune responses in the skin that produce redness (erythema), swelling (oedema), itching (pruritus), and structural changes to the epidermis and dermis.

In eczema, a defective skin barrier allows irritants and allergens to penetrate, triggering a type 2 immune response with T-helper cell activation and release of inflammatory cytokines including interleukin-4, interleukin-13, and interleukin-31.

In psoriasis, the immune response is predominantly type 1 and type 17, with T-cells driving keratinocyte hyperproliferation and neutrophil infiltration.

Regardless of the underlying immune pathway, topical corticosteroids suppress the inflammatory cascade at multiple points, providing rapid symptom relief.

The choice of corticosteroid potency depends on the severity and site of disease: mild preparations (hydrocortisone 1%) for the face and flexures, moderate for mild-moderate body involvement, potent (such as Diprosone) for moderate-severe body disease or resistant patches, and very potent (clobetasol propionate) for thick, resistant plaques under specialist supervision.

How Diprosone works: mechanism of action

Betamethasone dipropionate exerts its effects through genomic and non-genomic pathways.

The primary genomic mechanism involves the drug crossing the keratinocyte cell membrane and binding to the cytoplasmic glucocorticoid receptor (GR).

The activated GR-steroid complex translocates to the nucleus, where it modulates gene transcription in two ways.

It induces anti-inflammatory genes (transactivation), including those encoding lipocortin-1 (which inhibits phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis) and secretory leucocyte protease inhibitor.

Simultaneously, it represses pro-inflammatory genes (transrepression) by interfering with transcription factors NF-kB and AP-1, reducing expression of interleukins, TNF-alpha, chemokines, adhesion molecules, and inducible cyclooxygenase (COX-2).

The clinical result is a rapid reduction in the signs and symptoms of inflammation: less redness (due to vasoconstriction and reduced capillary permeability), less swelling (reduced oedema from decreased vascular leakage), less itching (reduced inflammatory mediators that stimulate sensory nerves), and reduced scaling (normalisation of epidermal turnover).

Betamethasone dipropionate is an enhanced-potency ester.

The dipropionate ester increases the lipophilicity of the molecule compared with betamethasone valerate, improving penetration into the lipid-rich stratum corneum and providing sustained local anti-inflammatory activity.

This is why Diprosone is classified as potent, while betamethasone valerate 0.025% (Betnovate-RD) is classified as moderate.

Clinical evidence and UK prescribing guidance

Topical corticosteroids are supported by decades of clinical evidence and are the most extensively studied class of dermatological therapy.

Betamethasone dipropionate 0.05% has been shown in randomised controlled trials to be effective in reducing eczema severity scores (SCORAD, EASI) and psoriasis severity (PASI) when used as directed.

Potent corticosteroids achieve disease control more rapidly than mild or moderate preparations, which is important for managing acute flares and reducing the itch-scratch cycle that perpetuates eczema.

NICE Clinical Knowledge Summaries on eczema recommend a stepped approach to topical corticosteroid use: mild for the face and flexures, moderate for mild flares on the body, and potent (such as Diprosone) for moderate to severe flares or for disease not responding to lower potencies.

For psoriasis, NICE recommends a potent topical corticosteroid as first-line for trunk and limb disease, applied for up to 4 weeks.

The BAD and Primary Care Dermatology Society guidelines emphasise the importance of adequate potency for adequate duration to gain control, followed by a step-down to maintenance with emollients and, where appropriate, lower-potency corticosteroids or non-steroidal agents such as calcineurin inhibitors (tacrolimus, pimecrolimus).

How to use Diprosone correctly

Cleanse the affected area gently and pat dry. If using an emollient alongside Diprosone, apply the emollient first and wait 20 to 30 minutes before applying the corticosteroid.

This interval prevents dilution of the active ingredient and inadvertent spread to unaffected skin.

Apply a thin layer of Diprosone to the affected area only. Use the fingertip unit (FTU) system to measure the correct amount.

One FTU is the amount of cream or ointment squeezed from the tube along an adult's fingertip (from the tip to the first crease); this covers approximately the area of two flat adult hands (palms plus fingers).

Apply once daily. Twice-daily application may be used for severe flares on medical advice but offers only marginally greater efficacy with increased risk of side effects.

Continue treatment until the acute flare has settled, typically within 1 to 2 weeks for eczema and 2 to 4 weeks for psoriasis.

Once control is achieved, step down to a milder corticosteroid, a non-steroidal topical agent, or emollient maintenance.

Your prescriber may recommend a proactive maintenance schedule for frequently relapsing eczema, such as applying Diprosone to previously affected areas twice weekly (weekend therapy) to prevent relapse.

Formulation choice

Cream is water-based, absorbs easily, and is suitable for moist, weeping, or flexural lesions.

Ointment is greasy and occlusive, providing better penetration for dry, thickened, or scaly skin but may be cosmetically less acceptable.

Lotion is the lightest formulation and is ideal for hairy areas including the scalp and for widespread application where ease of spreading is important.

Side effects of Diprosone

Common local side effects

Burning, stinging, or itching on initial application, skin dryness, and folliculitis are the most frequently reported local effects. These are generally mild and transient. They are more common with cream formulations (due to preservatives and emulsifiers) than with ointments.

Effects of prolonged use

Skin atrophy is the most clinically significant local adverse effect. The skin becomes thin, fragile, and translucent, with visible blood vessels (telangiectasia) and a tendency to bruise easily.

Striae (stretch marks) may form, particularly in flexural areas, and are permanent.

Other effects include hypopigmentation, hypertrichosis, acneiform eruptions, and perioral dermatitis or steroid rosacea (particularly with inappropriate facial use).

These effects are dose and duration dependent. They are most likely with prolonged continuous use, use of occlusive dressings, use on thin-skinned areas, and in young children.

Systemic effects

Systemic absorption sufficient to cause adrenal suppression is rare with standard short-course use but can occur with prolonged treatment over large areas, with occlusion, or in children.

Signs include fatigue, muscle weakness, and, in severe cases, adrenal crisis on withdrawal. Cushing syndrome features, hyperglycaemia, and growth retardation in children have been reported with excessive use.

When to seek medical advice

See your GP if you develop skin thinning, stretch marks, persistent or worsening irritation, or signs of skin infection.

Seek urgent medical advice if you experience signs of an allergic reaction (widespread rash, facial swelling, breathing difficulty).

Report adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Appropriate prescribing

Diprosone should only be used for diagnosed inflammatory skin conditions. It is not a moisturiser and should not be applied to unaffected skin.

Using the wrong potency of corticosteroid for the wrong site or duration is the most common cause of topical corticosteroid side effects.

Face and sensitive areas

Do not apply Diprosone to the face, eyelids, genital area, or skin folds unless specifically directed by a dermatologist.

These areas are particularly vulnerable to atrophy, striae, and steroid-induced rosacea.

If periorbital application is required, be aware of the risk of glaucoma and cataracts with prolonged use near the eyes.

Children

Use the minimum quantity for the shortest duration in children of all ages. Growth monitoring is advised with prolonged or repeated courses.

Nappy areas in infants act as occlusion and increase absorption significantly. Mild corticosteroids are generally preferred for routine paediatric use.

Infection

Corticosteroids suppress local immunity and can mask or exacerbate skin infections. Do not apply Diprosone to infected skin unless an appropriate antimicrobial is also being used. If a treated area becomes infected, stop the corticosteroid and treat the infection.

Withdrawal and rebound

Stopping a potent corticosteroid abruptly after prolonged use can trigger a rebound flare or, rarely, topical steroid withdrawal syndrome (red skin syndrome). Taper treatment gradually and step down to a lower potency under medical supervision.

Pregnancy and breastfeeding

The safety of betamethasone dipropionate during pregnancy has not been fully established.

Use potent topical corticosteroids during pregnancy only if the benefit outweighs the risk, in the smallest amount for the shortest time.

Avoid applying to the breast during breastfeeding to prevent inadvertent infant exposure.

Topical corticosteroid potency ladder

Understanding where Diprosone sits in the potency ladder helps patients and prescribers make informed choices. The BNF classifies topical corticosteroids into four potency groups.

Mild includes hydrocortisone 0.5 to 1% and is suitable for the face, flexures, and children. Moderate includes clobetasone butyrate (Eumovate) and betamethasone valerate 0.025%.

Potent includes betamethasone dipropionate 0.05% (Diprosone), betamethasone valerate 0.1% (Betnovate), and mometasone furoate (Elocon). Very potent includes clobetasol propionate (Dermovate).

The appropriate potency is matched to the severity, site, and nature of the skin condition.

How to get a Diprosone prescription in the UK

Diprosone is a prescription-only medicine. Your GP can prescribe it following a clinical assessment of your skin condition.

For eczema or psoriasis that is moderate to severe, widespread, or not responding to lower-potency corticosteroids, your GP may refer you to an NHS dermatologist.

Authorised online prescribers registered with the General Pharmaceutical Council (GPhC) can also issue prescriptions following clinical assessment.

The standard NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Living with eczema or psoriasis: practical advice

Regular emollient use (at least twice daily and after bathing) is the foundation of management for both eczema and psoriasis.

Emollients maintain the skin barrier, reduce water loss, and decrease the frequency and severity of flares. Use unperfumed products and apply generously.

Avoid known triggers where possible: common eczema triggers include soap, detergent, woollen clothing, house dust mite, and stress.

Psoriasis triggers include skin trauma (Koebner phenomenon), infections (especially streptococcal throat infections), stress, excessive alcohol, and certain medications (lithium, beta-blockers).

If your skin condition is significantly affecting your quality of life, sleep, work, or mental health, tell your GP.

Referral to specialist dermatology services, psychological support, and access to advanced therapies (phototherapy, systemic immunosuppressants, biologic therapies for psoriasis) are available through the NHS.

Sources

• Diprosone Cream 0.05%, Summary of Product Characteristics (EMC)
• Betamethasone (topical), British National Formulary (BNF)
• NICE CKS: Eczema, atopic
• NICE CKS: Psoriasis
• Eczema (atopic), NHS
• British Association of Dermatologists, Eczema
• MHRA Yellow Card Scheme